Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis — Probabli.AI
AI-powered analysis for AUPH (Aurinia Pharmaceuticals Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $14.32 · Market cap: $2.0B · AI outlook: Bullish
Aurinia Pharmaceuticals Inc. demonstrates strong growth potential due to its consistent earnings beats and promising drug pipeline. Despite supply chain issues and competitive pressures, the company's fundamentals and positive news highlight its momentum. The stock is positioned for above-average returns with upside potential from forthcoming clinical and regulatory outcomes.
Probabilistic 1-Year Outlook
- Bull 40% · Neutral 50% · Bear 10%
- 1-year price estimates — P10: $12 / P50: $16 / P90: $20
- With multiple positive catalysts, including a consistent earnings beat streak and FDA approvals, there is strong short-term bullish sentiment, moderated by competitive and supply chain concerns.
5-Year Outlook
- Bull 55% · Neutral 35% · Bear 10%
- 5-year price estimates — P10: $13 / P50: $27 / P90: $45
SWOT Highlights
- Strength: Consistent earnings beat streak
- Strength: High average EPS surprise, showcasing operational efficiency
- Risk: Intense competition in the lupus treatment market
- Risk: Supply chain issues impacting operations
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
4 Wall Street analysts rate AUPH a BUY with a mean price target of $17.25.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
AUPH forecast details · AUPH sentiment details · AUPH insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.